Tagged with US

Boehringer Ingelheim Russia You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you have stayed with Boehringer Ingelheim throughout executive positions in Germany, Portugal, Ukraine, Finland, and, of course, now Russia. What has…

IMS Russia You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market? For the IMS, in terms of strategic development, this was certainly a significant acquisition—because afterwards, the organization became the leading…

MSD Russia You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation prior to the interview, you mentioned that there has been a bit of a transition and adjustment period. How is…

Nycomed Russia-CIS Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as strategically and economically unattractive. What have been the evolutions in the market that have made construction of a Russian facility…

Celgene Russia Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and internal reasons, which coincided in this case. The external reason was the launch of the reimbursement system in Russia, which…

Russo-British Chamber of Commerce (RBCC) There is a long history of trade between Russia and Britain. The Chamber of Commerce started in 1916. Can you outline how the organisation has evolved and its current role today? As you point out, the Chamber was founded in 1916 – an interesting decision considering that we were in…

OctoPlus N.V. Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising. In your view, what makes OctoPlus stand out in the market? There are two main components, one being the people…

Utrecht Science Park (USP) Certain cities have specific institutions, foundations, or in this case, science parks that serve as a microcosm for that city. How does Utrecht Science Park embody the identity and strengths of the city of Utrecht? This science park has two focuses: life sciences and sustainability, which particularly focuses on climate…

Association of the British Pharmaceutical Industry (ABPI) Taking a look at a key achievement of the ABPI in recent years, we recognize the role you played in negotiating the revised PPRS that was put in place last year. How did the latest revision contribute to taking the research-based industry forward and what has been the impact of…

Association of the British Pharmaceutical Industry (ABPI) What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the recent history of the pharmaceutical industry in the UK, perhaps one of the areas that we have been most successful…

Philippine Chamber of the Pharmaceutical Indu The Philippine Chamber of Pharmaceutical Industries was established in 2004 from the merger of four different associations (Chamber of Filipino Drug Manufacturers and Distributors, Association of Drug Industries of the Philippines, Filipino Drug Association, and Association of Philippine Pharmaceutical Manufacturers). Can you tell to our readers what the rationale behind…

Korea Research based Pharmaceutical Industry Since KRPIA’s creation in 1999, what would you say have been its main achievements in the South Korean pharmaceutical landscape? KRPIA’s foremost achievement during its existence has been its contribution to bringing the focus on R&D to the pharmaceutical industry in South Korea. Our member companies spend between 17% and…